Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vomiting 5Nausea 5Neoplasms 4Hematologic Neoplasms 4Anorexia 3Multiple Myeloma 2Breast Neoplasms 2Testicular Neoplasms 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Prosthesis Failure 1Opioid-Related Disorders 1Nutrition Disorders 1Neoplasms, Plasma Cell 1Gynecologic Cancer 1Cachexia 1Advanced Cancer 1

Interventions

fosaprepitant 1Prochlorperazine 1Preoperative Exercise 1Ondansetron 1Olanzapine 1Neurokinin-1 Receptor Antagonists 1FloSeal Matrix 1Ferric Oxide, Saccharated 1Enhanced Recovery After Surgery 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Gynecologic Cancer × Olanzapine × Clear all
NCT04503668 2025-06-18

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

University of Michigan Rogel Cancer Center

Phase 3 Terminated
62 enrolled 16 charts
Gynecologic

Gynecologic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡